fluconazole
E561768
Fluconazole is a triazole antifungal medication commonly used to treat and prevent a wide range of Candida infections in humans.
Statements (53)
| Predicate | Object |
|---|---|
| instanceOf |
WHO Essential Medicine
ⓘ
azole antifungal ⓘ pharmaceutical drug ⓘ triazole antifungal drug ⓘ |
| activeAgainst |
Candida albicans
NERFINISHED
ⓘ
Cryptococcus neoformans NERFINISHED ⓘ other Candida species (variable susceptibility) ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| commonAdverseEffect |
abdominal pain
ⓘ
diarrhea ⓘ headache ⓘ nausea ⓘ |
| crosses | blood–brain barrier ⓘ |
| developedBy | Pfizer NERFINISHED ⓘ |
| discoveredIn | 1980s ⓘ |
| eliminatedBy | renal excretion ⓘ |
| eliminationHalfLife | approximately 20–50 hours in adults ⓘ |
| hasATCCode | J02AC01 ⓘ |
| hasBioavailability | high oral bioavailability ⓘ |
| hasBrandName | Diflucan NERFINISHED ⓘ |
| hasCASNumber | 86386-73-4 ⓘ |
| hasChemicalFormula | C13H12F2N6O ⓘ |
| hasDrugInteraction |
certain benzodiazepines
ⓘ
phenytoin NERFINISHED ⓘ some statins ⓘ sulfonylureas ⓘ warfarin NERFINISHED ⓘ |
| hasIUPACName | 2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol ⓘ |
| hasMechanismOfAction |
inhibits ergosterol synthesis in fungal cell membranes
ⓘ
inhibits fungal cytochrome P450 enzyme 14α-demethylase ⓘ |
| hasMolarMass | 306.27 g/mol ⓘ |
| hasProteinBinding | low to moderate protein binding ⓘ |
| hasRouteOfAdministration |
intravenous
ⓘ
oral ⓘ topical (some formulations) ⓘ |
| inhibitsEnzyme |
CYP2C19
NERFINISHED
ⓘ
CYP2C9 ⓘ CYP3A4 ⓘ |
| isOn | World Health Organization Model List of Essential Medicines NERFINISHED ⓘ |
| isWaterSoluble | yes ⓘ |
| notActiveAgainst |
Mucorales
NERFINISHED
ⓘ
most Aspergillus species ⓘ |
| pregnancyCategory | Category D in first trimester (US, systemic use) ⓘ |
| seriousAdverseEffect |
QT interval prolongation
ⓘ
hepatotoxicity ⓘ torsades de pointes (rare) ⓘ |
| usedFor |
prophylaxis of fungal infections in immunocompromised patients
ⓘ
treatment of candidemia ⓘ treatment of cryptococcal meningitis ⓘ treatment of esophageal candidiasis ⓘ treatment of oropharyngeal candidiasis ⓘ treatment of systemic Candida infections ⓘ treatment of vulvovaginal candidiasis ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.